

101. J. J. Medina, "The Epigenetics of Stress," *Psychiatric Times*, Apr. 7, 2010; vol. 27, no. 4. <https://www.psychiatristimes.com/view/epigenetics-stress>. Retrieved Apr. 29, 2021.
102. S. P. Megdal, et al. "Night work and breast cancer risk: A systematic review and meta-analysis," *European Journal of Cancer* (Oxford, UK: 1990), vol. 41, 13 (2005): 2023-32. doi:10.1016/j.ejca.2005.05.010.
103. E. McNeely, et al. "The self-reported health of U.S. flight attendants compared to the general population," *Environmental Health*, 13, 13 (2014); <https://doi.org/10.1186/1476-069X-13-13>.
104. D. Buettner and S. Skemp. "Blue Zones: Lessons from the world's longest lived." *American Journal of Lifestyle Medicine*, vol. 10, 5 318-321, Jul. 7, 2016. doi:10.1177/1559827616637066.

CHAPTER 2

1. N. Sipeki, et al. "Immune dysfunction in cirrhosis," *World J. Gastroenterol*, 2014;20(10):2564-2577. doi:10.3748/wjg.v20.i10.2564.
2. Wu SY, et al. "Natural killer cells in cancer biology and therapy," *Mol Cancer*, 2020;19(1):120, Aug 6, 2020. doi:10.1186/s12943-020-01238-x.
3. D. Ostroumov, et al. "CD4 and CD8 T lymphocyte interplay in controlling tumor growth." *Cell Mol. Life Sci.*, 2018; 75(4):689-713. doi:10.1007/s00018-017-2686-7.
4. M. Hoffman, et al. "Human acute and chronic viruses: Host-pathogen interactions and therapeutics," *Advanced Concepts in Human Immunology: Prospects for Disease Control*, 2020;1-120, Aug 12, 2020. doi:10.1007/978-3-030-33946-3_1.
5. A. Thakur, et al. "Intracellular pathogens: Host immunity and microbial persistence strategies." *J. Immunol. Res.* 2019;2019:1356540, Apr 14, 2019. doi:10.1155/2019/1356540.
6. A. M. van der Leun, et al. "CD8⁺ T cell states in human cancer: insights from single-cell analysis," *Nat. Rev. Cancer*. 2020;20(4):218-232. doi:10.1038/s41568-019-0235-4.
7. Ibid.
8. R. T. Lee, et al. "The sugar-combining area of the galactose-specific toxic lectin of mistletoe extends beyond the terminal sugar residue: Comparison with a homologous toxic lectin, ricin," *Carbohydr. Res.* 254, 269-276 (1994).
9. U. Pfüller. "Chemical constituents of European mistletoe (*Viscum album* L.)," in A. Büssing (ed.). *Mistletoe: The Genus Viscum*. Amsterdam: Harwood Academic, 2000, pp. 101-122.
10. W. Kreis. "Advances in structure elucidation of mistletoe constituents," in R. Scheer, et al. (ed.), *Die Mistel in der Tumorthherapie* 2. Essen: KVC Verlag, 2009, pp. 17-29.
11. G. S. Kienle and H. Kiene. *Mistletoe in Oncology. Facts and Basic Concepts*. New York: Schatauer, 2003.
12. H. Li, et al. "The structural basis of T cell activation by superantigens," *Annu. Rev. Immunol.*, 1999; 17:435-466. doi: 10.1146/annurev.immunol.17.1.435.

13. A. Galelli, et al. "Selective expansion followed by profound deletion of mature V beta 8.3+ T cells in vivo after exposure to the superantigenic lectin *Urtica dioica* agglutinin," *J. Immunol.*, Mar 15, 1995; 154(6):2600–11. PMID: 7876535.
14. A. Galelli and P. Truffa-Bachi. "Urtica dioica agglutinin. A superantigenic lectin from stinging nettle rhizome," *J. Immunol.*, Aug 15, 1993; 151(4):1821–31. PMID: 8345184.
15. U. Pfüller. "Chemical constituents of European mistletoe (*Viscum album* L.)," in A. Büssing (ed.). *Mistletoe: The Genus Viscum*, Amsterdam: Harwood Academic, 2000, pp. 101–122.
16. M. Franz. *Struktur und biologische Aktivitäten der chitinbindenden Mistellektine* (dissertation), Tübingen, 2003.
17. W. Kreis. "Advances in structure elucidation of mistletoe constituents," in R. Scheer, et al. (ed.). *Die Mistel in der Tumorthherapie* 2, Essen: KVC Verlag, 2009, pp. 17–29.
18. M. Giudici, et al. "Interaction of viscotoxins A3 and B with membrane model systems: Implications to their mechanism of action," *Biophys J.* Aug. 2003;85(2):971–81. doi: 10.1016/S0006-3495(03)74536-6. PMID: 12885644; PMCID: PMC1303218.
19. M. Yang and W. J. Brackenbury. "Membrane potential and cancer progression," *Front. Physiol.* Jul. 17, 2013; 4:185. doi: 10.3389/fphys.2013.00185. PMID: 23882223; PMCID: PMC3713347.
20. G. Ribereau-Gayon, et al.: Effects of mistletoe (*Viscum album* L.) extracts on cultured tumor cells. *Experientia* 42, 594–599 (1986).
21. A. Büssing: Biological and pharmacological properties of *Viscum album* L. In Büssing A (Ed.). *Mistletoe: The Genus Viscum*. Amsterdam: Harwood Academic, 2000, pp. 123–182.
22. J. E. Debreczeni, et al. "Structure of viscotoxin A3: Disulfide location from weak SAD data." *Acta. Cryst.* D59, 2125–2132 (2003).
23. H. Becker and J. M. Scher. "Short survey of the main components of European mistletoe (*Viscum album* L.)," in R. Scheer, et al. (ed.). *Fortschritte in Der Misteltherapie*. Essen: KVC Verlag, 2005, pp. 3–11.
24. U. Pfüller. "Chemical constituents of European mistletoe (*Viscum album* L.)," in A. Büssing A (ed.), *Mistletoe: The Genus Viscum*. Amsterdam: Harwood Academic, 2000, pp. 101–122.
25. M. Yang and W. J. Brackenbury. "Membrane potential and cancer progression," *Front. Physiol.* 2013 Jul 17;4:185. doi: 10.3389/fphys.2013.00185. PMID: 23882223; PMCID: PMC3713347.
26. M. Giudici, et al. "Interaction of viscotoxins A3 and B with membrane model systems: Implications to their mechanism of action," *Biophys. J.* 2003 Aug;85(2):971–81. doi: 10.1016/S0006-3495(03)74536-6. PMID: 12885644; PMCID: PMC1303218. (AUTHOR NOTE: "[viscotoxins] bind with high affinity to membranes containing negatively charged phospholipids.")
27. S. Fischer. *In vitro-Versuche zur T-Zellaktivität*. Stuttgart: Hippokrates Verlag, 1996, p. 168.
28. G. S. Kienle and H. Kiene. *Mistletoe in Oncology: Facts and Basic Concepts*. New York: Schatauer, 2003.

29. H. Becker and J. M. Scher. "Short survey of the main components of European mistletoe (*Viscum album* L.)," in R. Scheer, et al. (ed.). *Fortschritte in Der Misteltherapie*, Essen: KVC Verlag, 2005, pp. 3–11.
30. M. Hashemzaei, et al. "Anticancer and apoptosisinducing effects of quercetin in vitro and in vivo," *Oncol. Rep.* 2017 Aug;38(2):819–828. doi: 10.3892/or.2017.5766. Epub 2017 Jun 28. PMID: 28677813; PMCID: PMC5561933.
31. H. Becker and J. M. Scher. "Short survey of the main components of European mistletoe (*Viscum album* L.)." in R. Scheer, et al. (ed.). *Fortschritte in Der Misteltherapie*, Essen: KVC Verlag, 2005, pp. 3–11.
32. W. Dröge and R. Breikreutz. "Glutathione and immune function," *Proc Nutr. Soc.* 2000 Nov;59(4):595–600. doi: 10.1017/s0029665100000847. PMID: 11115795.
33. K. Urech, et al. "Triterpenes of mistletoe (*Viscum album*) in the "bird-lime" viscin and its antiproliferative activity," in R. Scheer, et al. (ed.). *Fortschritte in Der Misteltherapie*, Essen: KVC Verlag, 2005, pp. 3–11.
34. K. Hostanska, et al. "Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation," *Br J. Cancer.* 2003 Jun 2;88(11):1785–92. doi: 10.1038/sj.bjc.6600982. PMID: 12771996; PMCID: PMC2377150. (AUTHOR NOTE: This study used recombinant mistletoe lectin which means it was produced by bacteria as a specific, singular compound and not extracted from the plant at all.)
35. J. E. Felenda, et al. "Antiproliferative potential from aqueous *Viscum album* L. preparations and their main constituents in comparison with ricin and purothionin on human cancer cells," *Journal of Ethnopharmacology*, vol. 236, 2019, pp. 100–107; ISSN 0378-8741; <https://doi.org/10.1016/j.jep.2019.02.047>. (AUTHOR NOTE: This study found: "The complete mistletoe extract is more potent to inhibit tumor cell proliferation than isolated ML-1 at an equivalent concentration level.")
36. Table used with permission from Manufacturer Publication, in *Compendium of Mistletoe Therapy with Helixor® in Integrative Oncology* (n.d.), p. 8; <https://docplayer.net/57758605-Helixor-compendium-of-mistletoe-therapy-with-helixor-in-integrative-oncology-mistletoe-therapy-for-tumor-patients-bringing-life-to-life.html>.
37. G. Schrader-Fischer and K. Apel. "The anticyclic timing of leaf senescence in the parasitic plant viscum album is closely correlated with the selective degradation of sulfur-rich viscotoxins," *Plant Physiol.*, 1993; 101(3):745–749. doi:10.1104/pp.101.3.745.
38. K. Urech, et al. "Organ specific and seasonal accumulation of viscotoxin-isoforms in *Viscum album* ssp. album," *Phytomedicine*, vol. 18, supp. 1. 2011, p. S7, ISSN 0944-7113; <https://doi.org/10.1016/j.phymed.2011.09.064>. (<http://www.sciencedirect.com/science/article/pii/S094471131100434X>).
39. M Harmsma, et al. "Effects of mistletoe (*Viscum album* L.) extracts Iscador on cell cycle and survival of tumor cells," *Arzneimittelforschung*, Jun. 2006;56(6A):474–82. doi: 10.1055/s-0031-1296815. PMID: 16927529.

40. J. Tabiasco, et al. "Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity," *Eur. J. Biochem.*, May 2002;269(10):2591-600. doi: 10.1046/j.1432-1033.2002.02932.x. PMID: 12027898.
41. Increase in CD8(+) cells: N. E. Gardin. "Immunological response to mistletoe (*Viscum album* L.) in cancer patients: A four-case series," *Phytother. Res.*, Mar. 2009;23(3):407-11. doi: 10.1002/ptr.2643. PMID: 19003944.
42. Increase in Cytotoxic T cells: J. Beuth, et al. "Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside-specific lectin from mistletoe in breast cancer patients," *Clin. Investig.*, Aug. 1992;70(8):658-61. doi: 10.1007/BF00180280. PMID: 1392440.
43. W. B. Park, et al. "Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis," *Cancer Biother. Radiopharm.*, Oct. 2001;16(5):439-47. doi: 10.1089/108497801753354348. PMID: 11776761.
44. J. M. Moon, et al. "Effect of mistletoe on endometrial stromal cell survival and vascular endothelial growth factor expression in patients with endometriosis," *Int. J. Med. Sci.*, Oct. 2018 20;15(13):1530-36. doi: 10.7150/ijms.28470. PMID: 30443175; PMCID: PMC6216063.
45. F. Stirpe, et al. "Inhibition of protein synthesis by a toxic lectin from *Viscum album* L. (mistletoe)," *Biochem. J.*, 1980;190(3):843-45. doi:10.1042/bj1900843.
46. E. Kovacs, et al. "Improvement of DNA repair in lymphocytes of breast cancer patients treated with *Viscum album* extract (Iscaidor)." *Eur. J. Cancer*, 1991;27(12):1672-6. doi: 10.1016/0277-79(91)90443-h. PMID: 1782081.
47. J. M. Woynarowski and J. Konopa. "Interaction between DNA and viscotoxins: Cytotoxic basic polypeptides from *Viscum album* L.," *Hoppe Seylers Z. Physiol. Chem.*, Oct. 1980;361(10):1535-45. doi: 10.1515/bchm2.1980.361.2.1535. PMID: 7192684.
48. U. Elsässer-Beile, et al. "Biological effects of natural recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes *in vitro*," *J. Clin. Lab. Anal.*, 14, 255-59 (2000).
49. G. M. Stein and P. A. Berg. "Evaluation of the stimulatory activity of a fermented mistletoe lectin-1 free mistletoe extract on T-helper cells and monocytes in healthy individuals *in vitro*." *Arzneimittelforschung*, Jun. 1996;46(6):635-9. PMID: 8767357.
50. Lymphocytes and Neutrophils REF: N. E. Gardin. "Immunological response to mistletoe (*Viscum album* L.) in cancer patients: A four-case series," *Phytother. Res.*, Mar. 2009;23(3):407-11. doi: 10.1002/ptr.2643. PMID: 19003944.
51. Neutrophil (granulocyte) REF: R. Huber, et al. "Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects," *Eur. J. Med. Res.*, Oct. 2005 18;10(10):411-18. PMID: 16287602.
52. G. S. Kienle and H. Kiene. *Mistletoe in Oncology: Facts and Basic Concepts*. New York: Schatauer, 2003.

53. G. M. Stein, et al. "Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract," *Anticancer Res.*, Nov.–Dec. 2002; 22(6C):4215–19. PMID: 12553059.
54. G. M. Stein, et al. "Activation of dendritic cells by an aqueous mistletoe extract and mistletoe lectin-3 in vitro," *Anticancer Res.* Jan.–Feb. 2002;22(1A):267–74. PMID: 12017301.
55. C. N. Baxevanis, et al. "Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity," *Immunopharmacol. Immunotoxicol.*, Aug. 1998; 20(3):355–72. doi: 10.3109/08923979809034819. PMID: 9736441.
56. J. E. Talmadge, et al. "Role of NK cells in tumour growth and metastasis in beige mice," *Nature*, Apr. 1980 17;284(5757):622–24. doi: 10.1038/284622a0. PMID: 7366733.
57. E. Gorelik, et al. "Role of NK cells in the control of metastatic spread and growth of tumor cells in mice," *Int. J. Cancer*, Jul. 1982 15;30(1):107–12. doi: 10.1002/ijc.2910300118. PMID: 7118294.
58. C. Di Vito, et al. "NK cells to cure cancer," *Semin. Immunol.*, Feb. 2019;41:101272. doi: 10.1016/j.smim.2019.03.004. Epub 2019 May 10. PMID: 31085114.
59. S. Fischer, et al. "Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients," *Cancer Immunol. Immunother.*, May 1997;44(3):150–56. doi: 10.1007/s002620050367. PMID: 9191874.
60. G. Nikolai, et al. "Effect of a mistletoe extract (Iscaador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices," *In Vitro Cell Dev. Biol. Anim.*, Oct. 1997;33(9):710–16. doi: 10.1007/s11626-997-0129-8. PMID: 9358287.
61. U. Hohobhm. "Fever therapy revisited," *Br. J. Cancer*, 2005;92(3):421–25. doi:10.1038/sj.bjc.6602386.
62. P. Hegde, et al. "Viscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2," *PLoS One*, 2011;6(10):e26312. doi: 10.1371/journal.pone.0026312. Epub 2011 Oct 18. PMID: 22028854; PMCID: PMC3196571.
63. W. S. Chen, et al. "Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac," *Int. J. Cancer*, Mar. 2001 15;91(6):894–9. doi: 10.1002/1097-0215(200102)9999:9999<894::aid-ijc1146>3.0.co;2-#. PMID: 11275997.
64. F. Schad, et al. "Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy: A real-world observational multicenter analysis," *PLoS One*, Aug. 2018 27;13(8):e0203058. doi: 10.1371/journal.pone.0203058. PMID: 30148853; PMCID: PMC6110500.
65. T. Ostermann, et al. "A systematic review and meta-analysis on the survival of cancer patients treated with a fermented viscum album L. extract (Iscaador): An update of findings," *Complement Med. Res.*, 2020;27(4):260–71. English. doi: 10.1159/000505202. Epub 2020 Jan 10. PMID: 31927541.